SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is experiencing a significant surge due to a proposed merger with Applied Digital's cloud computing business, which would transform it into ChronoScale, an AI GPU compute platform. This move has ignited widespread discussion about a potential short squeeze fueled by the stock's low float and new AI sector exposure, with many anticipating substantial upside. However, some investors express caution regarding the deal's non-binding nature and the implications of existing EKSO shareholders holding a minority stake in the combined entity.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending due to a recently awarded eight-figure contract for spacecraft docking systems, fueling community discussions about its role in the rapidly expanding space infrastructure and defense sectors. Investors are actively debating its potential for a significant short squeeze, viewing it as an undervalued asset positioned for substantial growth in a market increasingly compared to the early stages of AI development.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is at the center of investor speculation ahead of an anticipated Department of Energy announcement on plutonium awards, a critical development for the small modular reactor sector powering future energy needs. The community is buzzing with bullish sentiment around this potential catalyst and strong technical indicators, while skeptics point to recent insider selling, share dilution, and the company's pre-revenue status as concerns impacting its valuation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing heightened volatility due to impending Chinese export restrictions on silver, set to take effect early next year, and strong industrial demand from sectors like EVs and AI. The community is deeply divided between those anticipating a historic supply squeeze and genuine price discovery, and others cautioning a speculative bubble fueled by recent market movements and past price suppression tactics.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intense speculation regarding a potential "black box warning" for mRNA COVID-19 vaccines, which proponents believe could significantly elevate its protein-based alternative. The community is also actively discussing a major partnership or acquisition for Novavax's combined flu/COVID vaccine and Matrix-M adjuvant, fueled by recent M&A activity in the sector and mounting pressure on current management from activist investor Shah Capital for decisive action.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is highly active amid strong Phase 3 data for relacorilant in platinum-resistant ovarian cancer, touted by many as a potential new standard of care and multi-billion-dollar opportunity. This pivotal news, coupled with encouraging survival data for its ALS program and an upcoming FDA decision for Cushing Syndrome, has intensified community discussions around the stock's underlying value and the potential for a massive short squeeze.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a focal point of discussion as investors anticipate potential breakthroughs at the upcoming CES 2026, with recent analyst upgrades fueling optimism for its voice AI solutions in the automotive and restaurant sectors. While many bulls highlight the company's debt-free status, rapid revenue growth, and substantial backlog, others express frustration over recent price drops and insider selling, questioning short-term trajectory amidst ongoing volatility. Community sentiment is divided between those expecting significant gains from its innovative agentic AI and potential profitability in 2026, and those wary of past volatility and the stock's struggle to maintain upward momentum.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is generating significant discussion as multiple near-term FDA decisions approach for its diverse pipeline, including a motion sickness treatment anticipated to potentially mitigate GLP-1 induced nausea. The community is keenly observing the improved regulatory dynamic with the FDA and evaluating the company's undervalued status given a strong balance sheet and several event-driven catalysts. Many traders are positioning for these binary events, drawing comparisons to other recent biotech stock movements.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to high anticipation for its upcoming CES 2026 programming, where it will showcase advancements in AI-powered marketing and its Athena platform, fueling community speculation around potential catalysts. Investors largely view the MarTech innovator as significantly undervalued, anticipating a major re-rating driven by strong fundamentals and its leadership in AI-driven customer intelligence.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical is trending following the disappointing Phase 3 trial results for its setrusumab drug in osteogenesis imperfecta, which failed to meet primary endpoints and triggered a significant stock decline. Community discussion is split, with many viewing the sharp market reaction as an overreaction, emphasizing the company's approved therapies and other pipeline assets as reasons for long-term potential. While analysts are recalibrating valuations, some still maintain positive ratings, reflecting a complex sentiment around the stock's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fidelis Insurance (NYSE:FIHL) Sets New 52-Week High - Here's What Happened

Fidelis Insurance (NYSE:FIHL) Sets New 12-Month High - Should You Buy...

Fidelis Insurance (NYSE:FIHL) Reaches New 1-Year High - Here's What Happened

Fidelis Insurance (NYSE:FIHL) Hits New 12-Month High - What's Next...

Fidelis Insurance (NYSE:FIHL) Sees Large Volume Increase - Here's Why

Fidelis Insurance (NYSE:FIHL) Sees Strong Trading Volume - What's Next...

Fidelis Insurance (NYSE:FIHL) Upgraded at Wall Street Zen

Wall Street Zen upgraded Fidelis Insurance from a "hold" rating to a "buy" rating in a research note on Saturday...

Fidelis Insurance (NYSE:FIHL) Hits New 52-Week High - Still a Buy?

Fidelis Insurance (NYSE:FIHL) Reaches New 52-Week High - What's Next...

Fidelis Insurance Holdings Limited (NYSE:FIHL) Given Average Recommendation of "Hold" by Analysts

Shares of Fidelis Insurance Holdings Limited (NYSE:FIHL - Get Free Report) have earned a consensus recommendation of "Hold" from the ten ratings firms that are presently covering the firm...

Ex-Dividend Reminder: Fidelis Insurance Holdings, XP and VFC

Looking at the universe of stocks we cover at Dividend Channel, on 12/10/25, Fidelis Insurance Holdings Ltd (Symbol: FIHL), XP Inc - Class A (Symbol: XP), and VF Corp. (Symbol: VFC) will all trade...

JPMorgan Chase & Co. Raises Stake in Fidelis Insurance Holdings Limited $FIHL

JPMorgan Chase & Co. grew its holdings in Fidelis Insurance Holdings Limited (NYSE:FIHL - Free Report) by 332.5% in the second quarter, according to its most recent disclosure with the SEC. The fund...

Fidelis Insurance Holdings Limited $FIHL Position Lowered by American Century Companies Inc.

American Century Companies Inc. lowered its position in shares of Fidelis Insurance Holdings Limited (NYSE:FIHL - Free Report) by 4.9% during the 2nd quarter, according to its most recent disclosure...

Fidelis Insurance Holdings Limited (NYSE:FIHL) Given Consensus Rating of "Hold" by Brokerages

Shares of Fidelis Insurance Holdings Limited (NYSE:FIHL - Get Free Report) have earned a consensus rating of "Hold" from the ten research firms that are currently covering the stock, MarketBeat...

Fidelis Insurance Holdings Ltd. serves as a a global specialty insurer, leveraging strategic partnerships to offer innovative and tailored insurance solutions. It operates through the following segments: Insurance and Reinsurance. The Insurance segment offers a diverse portfolio of specialty insurance products, including Property, Marine, Aviation, Cyber, and more, designed to provide capital efficiency, regulatory relief, and transaction facilitation, while utilizing reinsurance strategies to mitigate volatility and diversify exposures. The Reinsurance segment includes an actively managed property reinsurance book, providing reinsurance and limited retrocession coverage globally, with a significant focus on North America. The company was founded by Richard Brindle and Neil McConachie on August 22, 2014 and is headquartered in Hamilton, Bermuda.

Current Price	$19.63
Prev Close	$19.56
Open	$19.72
Dividend Yield	2.21%
50-Day Moving Average	$18.69
Beta	0.00
Avg. Volume	463,985.89
PE Ratio	-379.81

52-Week High	$19.83
52-Week Low	$14.17
Market Capitalization	$2.05B
EPS (Annual)	$0.9834
Price to Book	0.83
Revenue Per Employee	$24.73M
Enterprise Value/EBITDA	N/A

FIHL
Fidelis Insurance Holdings Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FIHL News

FIHLFidelis Insurance Holdings Ltd.